Gevorg Tamamyan: The Day We Decided War Will No Longer Mean the End of Cancer Care
Highlights From How I Treat Bladder Cancer in 2026: OncoDaily Virtual Summit
Yvonne Awards 2026
Dario Trapani: Launching WHO Academy Webinar Series on National Cancer Control Planning
OncoDaily Brings Sarcoma Experts Together at ASCO 2026
Helena Kremer: Brazilian Government Announces R$1.1 Billion Oncology Complex Integrated With INCA In Rio
King Hussein Cancer Research Award: Advancing Cancer Research Across the Arab World 2026
Grand Rounds by OncoDaily: AI in Oncology Edition
Enter RS and clinical context to view RS category and trial-aligned interpretation for early HR+/HER2- breast cancer.
This calculator is intended for ER/PR+ HER2- breast cancer only
TAILORx (Node-negative): Demonstrated that chemotherapy provides minimal to no benefit for most patients with RS 11-25. For patients ≤50 years, some benefit may be seen in RS 16-25.
RxPONDER (Node-positive, 1-3 nodes): Showed that postmenopausal patients with RS 0-25 did not benefit from chemotherapy. Premenopausal patients derived benefit regardless of RS.
RS Categories:
Low
0-10
Intermediate
11-25
High
26-100
